Limits...
The role of IL-33 and mast cells in allergy and inflammation.

Saluja R, Khan M, Church MK, Maurer M - Clin Transl Allergy (2015)

Bottom Line: IL-33 and mast cells have been influentially associated to the pathophysiology of allergic diseases and inflammation.IL-33 is a crucial regulator of mast cell functions and might be an attractive therapeutic target for the treatment of allergic and inflammatory diseases.In this review, we summarize the current knowledge regarding the roles of IL-33 and mast cells in the pathogenesis of allergies and inflammation.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Berlin, Germany ; Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh 462024 India ; Ramalingaswami Fellow, Department of Biotechnology, Government of India, New Delhi, India.

ABSTRACT
Interleukin-33 (IL-33) is a member of the interleukin-1 (IL-1) cytokine family. It is preferentially and constitutively expressed in different structural cells such as epithelial cells, endothelial cells, and smooth muscle cells. During necrosis of these cells (after tissue injury or cell damage), the IL-33 that is released may be recognized by different types of immune cells, such as eosinophils, basophils and, especially, mast cells. IL-33 needs the specific receptor ST2 (membrane-bound receptor) and Interleukin-1 receptor accessory protein heterodimer for its binding, which instigates the production of different types of cytokines and chemokines that have crucial roles in the exacerbation of allergic diseases and inflammation. IL-33 and mast cells have been influentially associated to the pathophysiology of allergic diseases and inflammation. IL-33 is a crucial regulator of mast cell functions and might be an attractive therapeutic target for the treatment of allergic and inflammatory diseases. In this review, we summarize the current knowledge regarding the roles of IL-33 and mast cells in the pathogenesis of allergies and inflammation.

No MeSH data available.


Related in: MedlinePlus

The IL-33/ST2 signaling pathway in mast cells. IL-33 is primarily expressed by different types of structural cells. Damage to these cells by external stimuli results in cell injury followed by release of IL-33. IL-33 can be neutralized by binding to soluble ST2 (sST2) or recognized by membrane bound ST2 receptor, which subsequently leads to activation of MyD88 dependent signaling pathways and the release of mast cell mediators that play important roles in the progression of allergic diseases
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4588911&req=5

Fig1: The IL-33/ST2 signaling pathway in mast cells. IL-33 is primarily expressed by different types of structural cells. Damage to these cells by external stimuli results in cell injury followed by release of IL-33. IL-33 can be neutralized by binding to soluble ST2 (sST2) or recognized by membrane bound ST2 receptor, which subsequently leads to activation of MyD88 dependent signaling pathways and the release of mast cell mediators that play important roles in the progression of allergic diseases

Mentions: Interleukin-33 is stored in the nucleus and secreted upon necrosis or damage and released in response to cell injury, infection or mechanical damage [27, 28]. The high levels of constitutive IL-33 may act as a novel alarmin (intracellular alarm signal released after cell injury) to alert the immune system after endothelial or epithelial cell damage during trauma or infection (Fig. 1) [7].Fig. 1


The role of IL-33 and mast cells in allergy and inflammation.

Saluja R, Khan M, Church MK, Maurer M - Clin Transl Allergy (2015)

The IL-33/ST2 signaling pathway in mast cells. IL-33 is primarily expressed by different types of structural cells. Damage to these cells by external stimuli results in cell injury followed by release of IL-33. IL-33 can be neutralized by binding to soluble ST2 (sST2) or recognized by membrane bound ST2 receptor, which subsequently leads to activation of MyD88 dependent signaling pathways and the release of mast cell mediators that play important roles in the progression of allergic diseases
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4588911&req=5

Fig1: The IL-33/ST2 signaling pathway in mast cells. IL-33 is primarily expressed by different types of structural cells. Damage to these cells by external stimuli results in cell injury followed by release of IL-33. IL-33 can be neutralized by binding to soluble ST2 (sST2) or recognized by membrane bound ST2 receptor, which subsequently leads to activation of MyD88 dependent signaling pathways and the release of mast cell mediators that play important roles in the progression of allergic diseases
Mentions: Interleukin-33 is stored in the nucleus and secreted upon necrosis or damage and released in response to cell injury, infection or mechanical damage [27, 28]. The high levels of constitutive IL-33 may act as a novel alarmin (intracellular alarm signal released after cell injury) to alert the immune system after endothelial or epithelial cell damage during trauma or infection (Fig. 1) [7].Fig. 1

Bottom Line: IL-33 and mast cells have been influentially associated to the pathophysiology of allergic diseases and inflammation.IL-33 is a crucial regulator of mast cell functions and might be an attractive therapeutic target for the treatment of allergic and inflammatory diseases.In this review, we summarize the current knowledge regarding the roles of IL-33 and mast cells in the pathogenesis of allergies and inflammation.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Berlin, Germany ; Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh 462024 India ; Ramalingaswami Fellow, Department of Biotechnology, Government of India, New Delhi, India.

ABSTRACT
Interleukin-33 (IL-33) is a member of the interleukin-1 (IL-1) cytokine family. It is preferentially and constitutively expressed in different structural cells such as epithelial cells, endothelial cells, and smooth muscle cells. During necrosis of these cells (after tissue injury or cell damage), the IL-33 that is released may be recognized by different types of immune cells, such as eosinophils, basophils and, especially, mast cells. IL-33 needs the specific receptor ST2 (membrane-bound receptor) and Interleukin-1 receptor accessory protein heterodimer for its binding, which instigates the production of different types of cytokines and chemokines that have crucial roles in the exacerbation of allergic diseases and inflammation. IL-33 and mast cells have been influentially associated to the pathophysiology of allergic diseases and inflammation. IL-33 is a crucial regulator of mast cell functions and might be an attractive therapeutic target for the treatment of allergic and inflammatory diseases. In this review, we summarize the current knowledge regarding the roles of IL-33 and mast cells in the pathogenesis of allergies and inflammation.

No MeSH data available.


Related in: MedlinePlus